PDT Partners LLC Makes New $730,000 Investment in Evolus, Inc. $EOLS

Key Points

• PDT Partners LLC has acquired a new stake in Evolus, Inc. (NASDAQ:EOLS), purchasing 60,651 shares valued at approximately $730,000.
• Insider David Moatazedi sold 16,582 shares, while Director Brady Stewart bought 30,000 shares, indicating mixed insider sentiment regarding the company's stock.
• Wall Street analysts have given Evolus a consensus rating of "Moderate Buy" with a price target averaging $21.25, despite some cutting their price targets significantly.

PDT Partners LLC bought a new stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 60,651 shares of the company's stock, valued at approximately $730,000. PDT Partners LLC owned about 0.09% of Evolus at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Frontier Capital Management Co. LLC acquired a new position in Evolus in the 4th quarter valued at about $2,648,000. Raymond James Financial Inc. acquired a new position in Evolus in the 4th quarter valued at about $575,000. Comerica Bank acquired a new position in Evolus in the 4th quarter valued at about $312,000. Tang Capital Management LLC raised its stake in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Rafferty Asset Management LLC acquired a new position in Evolus in the 4th quarter valued at about $115,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Trading Up 2.0%

Shares of NASDAQ EOLS traded up $0.15 on Friday, reaching $7.66. 534,857 shares of the company traded hands, compared to its average volume of 1,155,379. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. Evolus, Inc. has a fifty-two week low of $5.71 and a fifty-two week high of $17.82. The stock has a market capitalization of $495.45 million, a PE ratio of -7.82 and a beta of 1.07. The company has a 50 day moving average of $8.26 and a 200 day moving average of $10.16.

Insider Transactions at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the completion of the sale, the chief marketing officer owned 89,949 shares in the company, valued at approximately $675,516.99. The trade was a 5.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brady Stewart bought 30,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.82 per share, with a total value of $204,600.00. Following the acquisition, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. This trade represents a 51.17% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 133,627 shares of company stock worth $1,325,764 over the last 90 days. Company insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on EOLS shares. BTIG Research cut their target price on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. HC Wainwright dropped their price objective on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Evolus currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.